Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2005;46:1347-1354
Published online before print November 14, 2005, doi: 10.1161/01.HYP.0000193504.51489.cf
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
46/6/1347    most recent
01.HYP.0000193504.51489.cfv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by D’Amore, A.
Right arrow Articles by Thomas, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by D’Amore, A.
Right arrow Articles by Thomas, W. G.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Hypertrophy
Right arrowRelated Article

(Hypertension. 2005;46:1347.)
© 2005 American Heart Association, Inc.


Original Articles

The Angiotensin II Type 2 Receptor Causes Constitutive Growth of Cardiomyocytes and Does Not Antagonize Angiotensin II Type 1 Receptor–Mediated Hypertrophy

Angelo D’Amore; M. Jane Black; Walter G. Thomas

From the Department of Anatomy and Cell Biology (A.D., M.J.B.), Monash University, Clayton, Victoria, Australia; and Molecular Endocrinology Laboratory (A.D., W.G.T.), Baker Heart Research Institute, Prahran, Victoria, Australia.

Correspondence to Dr Walter Thomas, Baker Heart Research Institute, PO Box 6492, St. Kilda Rd Central, Melbourne, 8008, Australia. E-mail walter.thomas{at}baker.edu.au

Angiotensin II (Ang II) has important actions on the heart via type 1 (AT1) and type 2 (AT2) receptors. The link between AT1 receptor activation and the hypertrophy of cardiomyocytes is accepted, whereas the contribution of the AT2 receptor, which reportedly antagonizes the AT1 receptor, is contentious. This ambiguity is primarily based on in vivo approaches, in which the direct effect of the AT2 receptor and its modulation of the AT1 receptor (at the level of the cardiomyocyte) are difficult to establish. In this study, we used adenoviruses encoding AT1 and AT2 to coexpress these receptors in isolated cardiomyocytes, allowing a direct examination of the consequence of varying AT1/AT2 stoichiometry on cardiomyocyte hypertrophy. In myocytes expressing only the AT1 receptor, Ang II stimulation promoted robust hypertrophy (increased protein:DNA ratio and phenotypic changes) via activation of mitogen-activated protein kinases (MAPKs). Titration of the AT2 receptor against the AT1 receptor did not inhibit Ang II–mediated cardiomyocyte hypertrophy. Instead, basal and Ang II–mediated hypertrophy was increased in line with the amplified expression of the AT2 receptor, indicating a capacity for the AT2 receptor to enhance basal cardiomyocyte growth. Indeed, expression of the AT2 receptor alone resulted in hypertrophy; remarkably, this was unaffected by Ang II stimulation or the AT2 receptor–specific ligands PD123319 and CGP42112. Although previous studies have indicated that the AT2 receptor can antagonize MAPK activation via the AT1 receptor, we found no evidence for this in cardiomyocytes. Thus, the AT2 receptor promotes ligand-independent, constitutive cardiomyocyte hypertrophy and does not directly antagonize the AT1 receptor in this setting.


Key Words: angiotensin II • hypertrophy • myocytes • rats • receptors


Related Article:

The Continuing Saga of the AT2 Receptor: A Case of the Good, the Bad, and the Innocuous
Timothy L. Reudelhuber
Hypertension 2005 46: 1261-1262. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
EndocrinologyHome page
Y. Li, Y. Saito, K. Kuwahara, X. Rong, I. Kishimoto, M. Harada, Y. Adachi, M. Nakanishi, H. Kinoshita, M. Horiuchi, et al.
Guanylyl Cyclase-A Inhibits Angiotensin II Type 2 Receptor-Mediated Pro-Hypertrophic Signaling in the Heart
Endocrinology, August 1, 2009; 150(8): 3759 - 3765.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
E. R. Porrello, A. D'Amore, C. L. Curl, A. M. Allen, S. B. Harrap, W. G. Thomas, and L. M.D. Delbridge
Angiotensin II Type 2 Receptor Antagonizes Angiotensin II Type 1 Receptor-Mediated Cardiomyocyte Autophagy
Hypertension, June 1, 2009; 53(6): 1032 - 1040.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger
Designing Heart Performance by Gene Transfer
Physiol Rev, October 1, 2008; 88(4): 1567 - 1651.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. Leatherbury, Q. Yu, B. Chatterjee, D. L. Walker, Z. Yu, X. Tian, and C. W. Lo
A novel mouse model of X-linked cardiac hypertrophy
Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2701 - H2711.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Eguchi
Triple Twist Theory of Rho Inhibition by the Angiotensin II Type 2 Receptor
Circ. Res., May 23, 2008; 102(10): 1143 - 1145.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X. Yan, A. J. T. Schuldt, R. L. Price, I. Amende, F.-F. Liu, K. Okoshi, K. K. L. Ho, A. J. Pope, T. K. Borg, B. H. Lorell, et al.
Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1274 - H1281.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
M. Konigshoff, A. Wilhelm, A. Jahn, D. Sedding, O. V. Amarie, B. Eul, W. Seeger, L. Fink, A. Gunther, O. Eickelberg, et al.
The Angiotensin II Receptor 2 Is Expressed and Mediates Angiotensin II Signaling in Lung Fibrosis
Am. J. Respir. Cell Mol. Biol., December 1, 2007; 37(6): 640 - 650.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Mogi, M. Iwai, and M. Horiuchi
Emerging Concepts of Regulation of Angiotensin II Receptors: New Players and Targets for Traditional Receptors
Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2532 - 2539.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
P. K. Mehta and K. K. Griendling
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Am J Physiol Cell Physiol, January 1, 2007; 292(1): C82 - C97.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
H. Suzuki, K. Eguchi, H. Ohtsu, S. Higuchi, S. Dhobale, G. D. Frank, E. D. Motley, and S. Eguchi
Activation of Endothelial Nitric Oxide Synthase by the Angiotensin II Type 1 Receptor
Endocrinology, December 1, 2006; 147(12): 5914 - 5920.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Chen and J. L. Mehta
Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone
Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1738 - H1745.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. H. Strauss and A. S. Hall
Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox
Circulation, August 22, 2006; 114(8): 838 - 854.
[Full Text] [PDF]


Home page
HypertensionHome page
T. L. Reudelhuber
The Continuing Saga of the AT2 Receptor: A Case of the Good, the Bad, and the Innocuous
Hypertension, December 1, 2005; 46(6): 1261 - 1262.
[Full Text] [PDF]